676494-56-7

Usage

Uses

Used in Medicinal Chemistry:
3-Fluoro-4-(4-formylphenoxy)benzamide is used as a building block for the synthesis of pharmaceutical compounds due to its fluorinated and formyl groups, which can enhance the bioavailability and metabolic stability of drug candidates.
Used in Drug Development:
In the pharmaceutical industry, 3-Fluoro-4-(4-formylphenoxy)benzamide is utilized as a precursor in the development of new drugs, leveraging its reactivity and potential for chemical modification to create molecules with desired therapeutic properties.
Used in Chemical Research:
3-Fluoro-4-(4-formylphenoxy)benzamide serves as a subject of study in chemical research to understand its properties, reactivity, and potential applications in various chemical processes and reactions.

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 64248-62-0 3,4-Difluorobenzonitrile 
• 676494-55-6 3-fluoro-4-(4-formylphenoxy)benzonitrile 

Downstream Products

• 1174130-60-9 4-[4-[[2-(3,5-dimethylphenyl)pyrrolidin-1-yl]methyl]phenoxy]-3-fluorobenzamide 
• 1346133-12-7 3-fluoro-4-[4-[[ (2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]methyl]phenoxy]benzamide 
• 1346133-11-6 3-fluoro-4-[4-[[ (2S)-2-(3-fluorophenyl)pyrrolidin-1-yl]methyl]phenoxy]benzamide 
• 1174130-62-1 4-[4-[[(2R)-2-(3,5-dimethylphenyl)pyrrolidin-1-yl]methyl]phenoxy]-3-fluorobenzamide 
• 1174130-61-0 JSPA₀₆₅₀₈ 
• 1346133-10-5 3-fluoro-4-[4-[[2-(3-fluorophenyl)pyrrolidin-1-yl]methyl]phenoxy]benzamide 

Relevant academic research and scientific papers

HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS

The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the prepa

Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: Application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer

Arylphenylpyrrolidinylmethylphenoxybenzamides were found to have high affinity and selectivity for κ opioid receptors. On the basis of receptor binding assays in Chinese hamster ovary (CHO) cells expressing cloned human opioid receptors, (S)-3-fluoro-4-(4-((2-(3-fluorophenyl)pyrrolidin-1-yl)methyl) phenoxy)benzamide (25) had a Ki = 0.565 nM for κ opioid receptor binding while having a Ki = 35.8 nM for μ opioid receptors and a Ki = 211 nM for δ opioid receptor binding. Compound 25 was also a potent antagonist of κ opioid receptors when tested in vitro using a [35S]-guanosine 5′O-[3-thiotriphosphate] ([35S]GTP-γ-S) functional assay in CHO cells expressing cloned human opioid receptors. Compounds were also evaluated for potential use as receptor occupancy tracers. Tracer evaluation was done in vivo, using liquid chromatography-tandem mass spectrometry (LC/MS/MS) methods, precluding the need for radiolabeling. (S)-3-Chloro-4-(4-((2-(pyridine-3-yl)pyrrolidin-1-yl)methyl) phenoxy)benzamide (18) was found to have favorable properties for a tracer for receptor occupancy, including good specific versus nonspecific binding and good brain uptake.

KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST

A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.

DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST

A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3', E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.